. However, due to the rarity of ALCL, there is no large epidemiological study in the literature that focuses primarily on systemic ALK+ ALCL with extranodal involvement (ALK+ ALCL-E). In DLBCL, extranodal involvement has been shown to be associated with worse survival outcomes (Vargo et al, 2015) . However, two smaller studies on systemic ALCL showed that survival outcomes between patients with nodal ALCL and those with extranodal ALCL are not significantly different (Park et al, 2006; Guru Murthy et al, 2017) . In addition, primary disease site has been shown to be a significant prognostic factor in other NHLs, such as DLBCL, peripheral large B cell lymphoma and peripheral T cell lymphoma, unspecified, which leads to the proposal of distinct subtypes based on anatomic location (Li et al, 2014; Vermeer et al, 1996; Grange et al, 2007 Grange et al, , 2014 Senff et al, 2007; Su et al, 2017a) . Studying the association between disease site and survival can help to determine whether subgroups of patients may benefit from more aggressive treatment upfront (Su et al. 2017b) . However, to our knowledge, no large study in the literature has investigated the significance of primary disease site as a prognostic factor for ALK+ ALCL-E (Su et al, 2018) .
The primary aim of our study was to compare the survival outcomes of ALK+ ALCL-E patients among different primary disease sites while controlling for patient and disease characteristics, socioeconomic factors and treatments received.
Material and methods

Patient population
The National Cancer Data Base (NCDB), a joint project between the American College of Surgeons and American Cancer Society, was used to identify ALK+ ALCL-E patients diagnosed between 2004 and 2014. The data used in this study were derived from a de-identified NCDB file. The American College of Surgeons and the Commission on Cancer have not verified and are not responsible for the analytical or statistical methodology employed, or the conclusions drawn from these data by the investigator. In our study, we identified patients to be included in the patient cohort within the NCDB database by using the International Classification of Diseases for Oncology, 3rd Edition (ICD-O-3) morphological code 9714. Patients with ALKÀ ALCL could not be included, because ALKÀ ALCL morphology was grouped under peripheral T cell lymphoma, not otherwise specified with the ICD-O-3 morphological code 9702. Information extracted from the user participant files encompassed demographic information (i.e. treatment centre, age of diagnosis, sex, primary insurance payer, median income), clinical information (i.e. Charlson-Deyo score, clinical stage, primary site of disease), treatment received (i.e. radiotherapy, chemotherapy, surgery, hormone therapy), length of follow-up and overall survival (OS). Clinical staging was determined using the TNM staging system (American Joint Committee on Cancer, 2016). Patients with ALK+ ALCL-E who satisfied inclusion criteria were then compared based on primary disease site. Primary disease sites were grouped into major groups (chest/abdomen/pelvis, bone, central nervous system [CNS] , head and neck, cutaneous/soft tissue) based on both location and organ system (Table SI) .
Statistical analysis
Chi-square test and Kruskal-Wallis test were used to evaluate differences in socioeconomic, demographic and clinicopathological characteristics among patients with various primary disease sites. A Kaplan-Meier estimate followed by the logrank test was used to evaluate differences in OS. Cox regression was used to evaluate independent predictors associated with survival, while comparison of OS among primary disease sites was performed using propensity score matching in a one to one manner to account for unmeasured and measured confounders ("MatchIt" package in R version 3.3.0; https://gking. harvard.edu/matchit). A forward-step Cox regression was performed, in which clinicopathological and sociodemographic characteristics were first evaluated on univariate analysis, and statistically significant predictors, defined as P < 0Á05, were then incorporated into multivariate analysis. For each primary disease site, pair-wise propensity matched analysis was performed to assess OS. Statistical significance was considered when P ≤ 0Á05. Statistical analysis and figures were generated with JMP 11.2.1 statistical software (SAS Institute Inc., Cary, NC, USA).
Results
A total of 1306 patients with ALK+ ALCL-E were identified using the NCDB (Table I) . Patients with ALK+ ALCL-E presented with a variety of disease sites: 387 (29Á6%) with disease presentation in the chest/abdomen/pelvis, 103 (7Á9%) in the bone, 62 (4Á7%) in the CNS, 134 (10Á3%) in the head and neck and 620 (47Á5%) in the cutaneous/soft tissue. Patients with disease presentation in the chest/abdomen/pelvis and bone had the highest proportions of Stage IV disease (38Á7% and 47Á6%, respectively). Patients with disease either in the CNS or in the cutaneous/soft tissue had the highest proportions of Stage I disease (61Á3% and 58Á7%, respectively). Patients with disease presentation in the bone additionally had the highest proportion of those receiving chemotherapy (83Á5%) and hormone therapy (59Á2%), while individuals with disease affecting the CNS had the highest proportion of Charlson-Deyo Score of 2 (17Á7%) and individuals receiving surgery (45Á2%).
The 5-year OS rate of the entire ALK+ ALCL-E cohort was 57Á5% (Fig 1A) . When stratified by primary disease site, those with disease presentations in the CNS and chest/abdomen/pelvis had shorter OS than those located in the head and neck, bone, and cutaneous/soft tissue at both 5 and 10 years (log-rank P < 0Á0001) ( Fig 1B) .
On multivariate Cox regression analysis, older age (Hazard ratio 95% CI: 1Á81-3Á24, P < 0Á001) and higher clinical stage (Stage IV vs. Stage I, HR: 2Á62, 95% CI: 2Á05-3Á35, P < 0Á001) were associated with shorter OS (Table II) .
Patients receiving either radiation treatment (HR: 0Á771, 95% CI: 0Á625-0Á951, P = 0Á0152) or chemotherapy (HR: 0Á594, 95% CI: 0Á478-0Á738, P < 0Á001) exhibited more favourable survival outcomes, while individuals of African American race compared to Caucasian race (HR: 1Á66, 95% CI: 0Á720-1Á10, P < 0Á001), those with disease present in the CNS compared to compared to cutaneous/soft tissue (HR: 2Á35, 95% CI: 1Á55-3Á55, P < 0Á001), bone compared to cutaneous/soft tissue (HR: 1Á55, 95% CI: 1Á05-2Á31, P = 0Á0308), or chest/ abdomen/pelvis compared to cutaneous/soft tissue (HR: 2Á19, 95% CI: 1Á75-2Á74, P < 0Á001) demonstrated poorer survival outcomes.
A propensity score matched analysis based on significant predictors of OS on univariate Cox analysis including age at diagnosis, Charlson-Deyo score, median income quartile, race, insurance status, clinical stage and treatments (radiation, chemotherapy and hormone therapy) was performed in a pair-wise fashion among primary disease sites. Results of each independent pair-wise comparison between every two primary disease sites are shown in Table III . After propensity score matching, the covariates were well-balanced ( Figure S1 ), and significant differences in OS persisted (P < 0Á001) among various disease sites, as patients with disease manifestations in the chest/abdomen/pelvis and CNS demonstrated shorter OS than those located in the head and neck, bone and cutaneous/ soft tissue.
Discussion
Given the rarity of ALK+ ALCL-E, there is no large study in the literature that focuses specifically on this subtype. Previous studies investigating prognostic factors of survival in ALK+ ALCL are limited by small cohort size, and, more importantly, fail to separate those with nodal from with extranodal involvement, which have been shown to have different survival outcomes in DLBCL (Al-Hamadani et al, 2015; Hapgood & Savage, 2015; Vargo et al, 2015; Guru Murthy et al, 2017) . Therefore, the prognostic factors for ALK+ ALCL-E remain unclear. Furthermore, it is unknown if there are specific subgroups of patients with worse prognosis who may benefit from more aggressive treatments. Our study showed that primary disease site was a significant determinant of OS for patients with ALK+ ALCL-E after adjusting for disease characteristics, socioeconomic factors and treatments received. Specifically, patients with disease manifestations in the CNS and chest/abdomen/pelvis had shorter OS than those with disease located primarily in the bone, head and neck, and cutaneous/soft tissue.
The 5-year OS rate in our study was 56Á4%, which is slightly higher than the 49Á3% reported in a study of 1604 patients with ALK+ ALCL using the Surveillance, Epidemiology and End Results (SEER) registry (Guru Murthy et al, 2017) . However, several smaller studies (n = 28-87) demonstrated a 5-year OS rate ranging from 70% to 90%, which is more favourable than that reported by our study (Gascoyne et al, 1999; Suzuki et al, 2000; Savage et al, 2008; Vose et al, 2008; Sibon et al, 2012; Parrilla Castellar et al, 2014) . Nevertheless, besides the smaller sample size, all previous studies included systemic ALK+ ALCL patients with both nodal and extranodal involvement, while our study focused exclusively on those with extranodal involvement. Two large retrospective studies on DLBCL, one of 59 255 patients with stage I and II disease from the NCDB and the another of 1575 patients from the Danish Lymphoma Group, showed that the presence of extranodal disease was a significant predictor of shorter OS (Moller et al, 2003; Vargo et al, 2015) . Thus, the less favourable survival outcomes of ALK+ ALCL-E in our cohort when compared to those of previous studies could be attributed to the exclusion of the nodal subtype in our study.
Although the specific extranodal sites of patients with ALK+ ALCL-E have been reported in a few studies (Park et al, 2006 (Park et al, , 2008 Savage et al, 2008; Guru Murthy et al, 2017) , only one study evaluated the prognostic significance of primary extranodal site (Guru Murthy et al, 2017) . In a study of 327 patients with ALK+ ALCL-E using the SEER database, Guru Murthy et al (2017) showed that ALK+ ALCL-E located in the thorax, abdomen and neurological tissues had worse prognosis than those located in the bone and soft tissue, head/neck and breast. Likewise, in a study of 755 patients with non-cutaneous, non-leukaemic peripheral T-cell lymphomas from the Swedish Lymphoma Registry, among whom 68 had ALK+ ALCL, Ellin et al (2014) showed that gastrointestinal (GI) involvement was associated with significantly poorer prognosis. Another study of 25 992 patients with DLBCL from the NCDB showed that GI, liver/pancreas, and pulmonary primary sites were associated with worse OS, while head and neck was associated with better survival (Castillo et al, 2014) . Similar to these studies, our study showed that ALK+ ALCL-E primarily located in the CNS and chest/ abdomen/pelvis (which included the GI system, liver and pancreas), was associated with shorter OS than that located in the head and neck, bone and soft tissue. However, these studies on ALCL are limited by relatively small sample size.
In the study reported by Guru Murthy et al (2017) , the longer OS associated with breast, head and neck cases were attributed to younger age at diagnosis and less advanced disease stage. In contrast, disease site remained a significant prognostic factor on multivariate analysis in our study after accounting for confounding factors, and the survival trend among different primary sites persisted in propensity-score matched analysis.
Our study suggests that the different survival outcomes among disease sites may be related to the underlying biology of disease. A study of 123 patients with DLBCL (41% extranodal) treated at two hospitals in Korea showed that BCL6 expression, a marker strictly regulated during B cell ontogeny, varied significantly among different primary sites of extranodal DLBCL (P = 0Á009) (Kim et al, 2011) . In addition, studies have suggested different aetiologies for extranodal lymphomas located at different sites. For example, B cell lymphoma of the thyroid gland was associated with Hashimoto's thyroiditis, while Helicobacter pylori infection was associated exclusively with NHL affecting the stomach (Hyjek & Isaacson, 1988; Wotherspoon et al, 1991) . Whether this difference in survival among primary extranodal sites is related to different aetiologies and/or genetic heterogeneity remains unknown and requires further investigation. However, physicians should treat patients with ALK+ ALCL-E located primarily in the CNS and chest/abdomen/pelvis more aggressively than those with disease in the bone, head and neck, and cutaneous/soft tissue, given their worse survival outcomes.
Besides primary disease site, our study showed that African American patients had significantly shorter OS than Caucasian patients. A similar racial disparity between African American and Caucasian patients was previously observed by Guru Murthy et al (2017), of 1604 patients with ALK+ ALCL, and in studies on other types of T cell lymphoma, such as mycosis fungoides (Weinstock & Gardstein, 1999; Nath et al, 2014; Su et al, 2017c) . In addition, our study showed that patients who received radiotherapy and chemotherapy had significantly improved survival outcomes. Likewise, the study by Murthy et al, showed that patients who received radiotherapy had significantly longer OS than those who did not on multivariate analysis. However, the investigation on therapy reported by Guru Murthy et al (2017) was limited because there was no data on chemotherapy. Future studies focusing specifically on race and treatment are needed in order to decipher the underlying aetiology of the racial disparity between African American and Caucasian patients, and to determine if there are subgroups of patients who benefit more from chemo-and radiotherapy.
Even though the strengths of our study include the largest patient cohort to date with relatively complete information on patient and diseases characteristics, we acknowledge a few limitations. First, our study is retrospective. Second, our data lacked central pathological review. Although the morphological Disease Sites in Primary Extranodal Systemic ALK+ Anaplastic Large Cell Lymphoma ª 2018 John Wiley & Sons Ltd code we used as the inclusion criteria clearly only included ALK+ ALCL-E patients, other lymphomas, such as ALKÀ ALCL, with extranodal involvement could potentially have been misclassified as ALK+ ALCL-E, particularly because ALK+ ALCL encompasses a broad spectrum of morphology (Benharroch et al, 1998) . Third, we did not have data on some key factors included in the International Prognostic Index that have been shown to contribute to prognosis of patients with ALCL, such as serum lactate dehydrogenase level and the Eastern Cooperative Oncology Group performance status (Gascoyne et al, 1999; Suzuki et al, 2000; ten Berge et al, 2003; Savage et al, 2008; Sibon et al, 2012; Ellin et al, 2014; Hapgood & Savage, 2015) . Lastly, NCDB does not include data on disease extent. Consequently, these factors could not be incorporated into our multivariable analysis. Similarly, there were no data on disease recurrence. Hence, progression-free or disease-specific survival could not be evaluated.
Conclusion
The primary disease site is a significant prognostic factor for patients with ALK+ ALCL-E after adjusting for disease characteristics, socioeconomic factors and treatment received. Patients with ALK+ ALCL-E localized to chest/abdomen/ pelvis and CNS had shorter OS than those localized in cutaneous/soft tissue, head and neck, and bone. We suggest that the worse prognosis may be related to differences in underlying biology. Our results also highlight the importance of further investigation into the molecular mechanisms underlying the different survival outcomes of patients with ALK+ ALCL-E among various anatomical sites, who warrant individualized treatment in the clinical setting.
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